Viral respiratory tract infections are a common cause of early childhood illness. Most of these infections are short-lived and self-limited, but some can be severe enough to require hospitalization. Indeed, viral respiratory tract infections are associated with 20% of all mortality in children less than 5 years of age.[@bib1] In addition to the morbidity of the acute infection, viral respiratory tract infections with wheezing are strong indicators of subsequent asthma.[@bib2], [@bib3] Therefore predicting those infants at risk for respiratory tract infections is an important first step in preventing acute and chronic respiratory disease. Previous studies have identified a variety of potential risk factors for viral lower respiratory tract infections during the first year of life. These factors include day care attendance, number of siblings, small lung size, exposure to tobacco smoke, low birth weight, and premature birth.[@bib3], [@bib4], [@bib5], [@bib6] Infections caused by respiratory syncytial virus (RSV) are particularly implicated in acute illness and chronic lung disease in the first 2 years of life.[@bib7] However, the majority of RSV infections in infants occur without any known risk factors.[@bib8] Thus we still do not understand the precise mechanism for the wide variation in susceptibility to severe respiratory tract infections among children in these settings.

One possible explanation for the range of susceptibility to viral respiratory tract infection in early childhood is that there are definable variations in the antiviral response, such as a congenital deficiency in the innate immune response that can be detected even at the time of birth. A central ingredient of the innate immune response to respiratory viruses is the system for interferon production and signaling.[@bib9] In that regard a decrease in IFN-γ production from cord blood mononuclear cells (CBMCs) stimulated by PHA or allergens has been associated with increased risk for acute respiratory tract illness during infancy.[@bib10], [@bib11] Perhaps more relevant to viral infection, the lack of a detectable IFN-γ response to RSV in CBMCs was associated with decreased wheezing in the first year of life, but a detectable response was only found in a third of subjects, and therefore predictive power was limited.[@bib12] Therefore in the present study we developed alternative methods to determine whether the innate immune response of virus-infected CBMCs could predict the later development of respiratory tract illness. We used RSV to activate CBMCs based on the well-established association of RSV infection with subsequent childhood asthma.[@bib2], [@bib13], [@bib14] However, to monitor the innate immune response to RSV, we determined the induction of the genes encoding IFN-γ and the remarkably virus-responsive chemokine CCL5 based on sensitive and quantitative methods for mRNA detection.[@bib15] We also monitored interferon signal transduction by tracking the level of signal transducer and activator of transcription (STAT) 1 activation in response to IFN-β stimulation. In both cases we used cultured/adherent CBMCs to select for monocytes versus the mixed cell population that included T cells in previous studies. We assessed whether each of these immune end points could predict the development of respiratory tract illness during the first year of life in a prospective birth cohort of children at high risk for asthma and allergic disease. The experimental matrix led to the unexpected finding of RSV-induced *IFNG* gene expression in monocytes as a predictor of subsequent viral respiratory tract illness.

Methods {#sec1}
=======

Study population {#sec1.1}
----------------

We analyzed cord blood samples from 82 newborns enrolled in the Urban Environment and Childhood Asthma (URECA) study. This group represents a subset of the 178 children enrolled at the St Louis site, which in turn was a subset of the total number of children enrolled at the Baltimore, Boston, and New York city sites between February 2005 and March 2007, as described previously.[@bib16], [@bib17], [@bib18] Subjects were required to have at least 1 parent with allergic rhinitis, eczema, and/or asthma and to reside in an area with greater than 20% of the residents below the poverty level, as well as being born at 34 weeks\' gestation or later. At the St Louis site, a small number of children without an allergic parent (n = 5) were also recruited for comparison. After enrollment, all subjects were monitored for any episodes of acute respiratory tract illness over the next year along with quarterly assessments of respiratory (and nonrespiratory) tract illness and wheezing by questionnaire. Nasal lavage samples were obtained when a caregiver reported an acute respiratory tract illness and at the time of a 1-year follow-up visit. The Washington University Human Research Protection Office approved the study protocol.

CBMC culture {#sec1.2}
------------

Cord blood samples were collected in the delivery room, and CBMCs were isolated by means of density gradient centrifugation with Accuspin tubes (Sigma, St Louis, Mo) within 16 hours of collection, as described previously.[@bib17], [@bib19] When sufficient amounts of sample were available (ie, in 82/178 subjects), the cells were resuspended in RPMI medium with 10% FBS, 2 mmol/L [l]{.smallcaps}-glutamine, and 1 mmol/L nonessential amino acids to a final concentration of 8 × 10^5^ per milliliter and plated in 4-well Lab-Tek chambers (500 μL per well; Nunc A/S, Roskilde, Denmark) for the real-time PCR assay and in 2-well Lab-Tek chambers (1 mL per well) for the STAT1 activation assay, as described below. Nonadherent cells were removed after 24 hours, and adherent cells were cultured for 5 days with media changes on days 1, 2, and 4 and removal of additional nonadherent cells. At the end of the cell-culture period, the adherent cells were greater than 95% positive for CD68 immunostaining as a marker of monocytic lineage and therefore designated as cord blood monocyte cultures. The approach avoided purification methods (eg, magnetic bead selection or fluorescence-activated cell sorting) that modify the cell membrane or cell-culture methods (eg, growth factor supplementation) that promote full differentiation and polarization and thereby aimed to obtain cells of the monocyte lineage that were representative of naive lung tissue monocytes and macrophages (the target for viral respiratory tract infection *in vivo*).

Analysis of antiviral response {#sec1.3}
------------------------------

On culture day 5, cord blood monocytes were infected with RSV (A2 strain) at a multiplicity of infection of 7.5 or an equivalent amount of UV-inactivated respiratory syncytial virus (RSV-UV). Cellular RNA was isolated immediately and 24 hours after inoculation with the RNAeasy mini kit (Qiagen, Valencia, Calif) and transcribed to cDNA by using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, Calif). Single-target quantitative real-time PCR was used to monitor *IFNG* and *CCL5* mRNA and RSV RNA levels. For *IFNG* and *CCL5* mRNA, primers were obtained from Applied Biosystems (Hs00174575_A1 and Hs00174143_A1). For RSV RNA, primers 5312F (5′-TCCCTACGGTTGTGATCGATAGA-3′) and 5396R (5′-TGATGGGAAGTAGTAGTGTAAAGTTGGT-3′) and probe 5349T (5′-AGGTAATACAGCCAAATC-3′) targeting the viral L gene were based on the sequence of RSV strain CRD2 (GenBank accession no. [DQ340570](ncbi-n:DQ340570)). For glyceraldehyde-3-phosphate dehydrogenase *(GAPDH)* mRNA, primers 50F (5′-CAGCCGAGCCACATCCCTCAGACACCAT-3′) and 125R (5′-CTTTACCAGAGTTAAAAGCAGCCCTGGTGACCA-3′) and probe 88T (5′-AGGTCGGAGTCAACCGATTTGGTCGTATTG-3′) were used. Plasmids encoding *CCL5* and *IFNG* (OriGene, Rockville, Md) and a portion of the RSV L gene (nt 5400-7016) and *GAPDH* gene sequence (GenBank accession no. [NM_002046](ncbi-n:NM_002046)) were used to generate RNA standards. RT-PCR was performed by using TaqMan real-time PCR Master Mix with 5 μL of sample cDNA in accordance with the manufacturer\'s protocol (Applied Biosystems). All data for gene copy number was normalized to *GAPDH* level.

STAT1 activation assay {#sec1.4}
----------------------

In a subset of cord blood samples (n = 63) with an adequate number of cells, we also assessed interferon signal transduction by monitoring the level of STAT1 phosphorylation in response to interferon stimulation. The corresponding CBMCs were processed as described above and serum starved on day 4 of culture. On culture day 5, the cells were incubated with IFN-β (100 U/mL) for 30 minutes. Cell lysate was harvested after treatment with cell lysis buffer (Cell Signaling, Danvers, Mass). The level of total STAT1 was determined by using ELISA (Invitrogen, Carlsbad, Calif), and phosphorylated STAT1 (Tyr701) levels were determined by using a sandwich ELISA (PathScan Phospho-Stat1, Cell signaling).

Viral monitoring {#sec1.5}
----------------

Nasal lavage samples were obtained during acute respiratory tract illnesses during the first year of life and at the 1-year follow-up visit. For illness samples, a respiratory symptom scorecard was completed as described previously.[@bib10], [@bib18] When the score indicated a moderate-to-severe respiratory tract illness, the site staff obtained a nasal lavage sample within 48 hours. All nasal lavage samples were processed for identification of 9 respiratory tract viruses by using a PCR-based assay, as described previously.[@bib18]

Statistical analysis {#sec1.6}
--------------------

Descriptive data were expressed as percentages, means ± SDs, or medians with interquartile ranges for nonnormally distributed data. To test differences between specific groups, χ^2^ or Fisher exact tests were used to compare categorical variables, whereas unpaired *t* tests were used to compare continuous variables. Appropriate log transformations were made to the data to yield an approximately normal distribution. For nonnormally distributed data, the Wilcoxon rank sum tests (Mann-Whitney *U* tests) were used to compare groups. Each measurement was standardized as the ratio over control to minimize variability in day-to-day experiments as follows:•*IFNG* mRNA response to RSV = *IFNG* mRNA copies with RSV*/IFNG* mRNA copies without RSV,•*CCL5* mRNA response to RSV = *CCL5* mRNA copies with RSV infection/*CCL5* mRNA copies with no RSV infection, and•STAT1 phosphorylation with IFN-β = (P-STAT1 with IFN-β/Total STAT1 with IFN-β)/(P-STAT-1 no stimulation/Total STAT1 no stimulation).

RSV level was expressed as the RSV RNA copy number with infection minus the value for no infection. Spearman correlations were calculated to test for associations between variables. We examined the possibility of confounding by the following variables: sex, breast-feeding, maternal smoking during pregnancy and the first year of the child\'s life, an overall sum of bedroom allergen exposure (*Mus musculus*, *Blattella germanica*, and *Felis domesticus*), and exposure to endotoxin (recombinant factor C assay) and ergosterol. We evaluated whether any of these variables were associated with the outcomes under analysis, and we found only that maternal smoking during the first year of life was related to the pneumonia outcome and the sum of bedroom allergen exposures was related to sinus infections. However, in logistic models controlling for these variables, the odds ratios changed by less than 5% when adjusted, and therefore we present unadjusted relationships here. All statistical tests were 2-tailed, and *P* values of less than .05 were considered statistically significant. Statistical procedures were conducted with both SAS 9.2 (SAS Institute, Inc, Cary, NC) and R 2.12.2 software.

Results {#sec2}
=======

Subjects\' demographics and first-year outcomes {#sec2.1}
-----------------------------------------------

We processed all cord blood samples that contained an adequate number of cells, representing 82 of the total of 178 children who were enrolled at the St Louis site of the URECA cohort. Among the 82 newborns, 85% of the babies were African American, the mean age of the mother at the time of delivery was 23.7 years, and 63% of the infants had at least 1 parent with asthma ([Table I](#tbl1){ref-type="table"} ). Subjects were reported to have an average of 4.2 upper respiratory tract infections (colds), 1.3 wheezing illnesses, and an all-cause hospitalization rate of 15% during the first year of life. The basic demographics and first-year outcomes for this group of 82 children were not significantly different from those of the remaining group of 96 children who were not part of the present analysis (see [Table E1](#dtbl1){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org)).Table IBaseline demographics and 1-year outcomes of the study populationCharacteristics (n = 82)Baseline demographics Female sex, no. (%)46 (56) Age (y) of mother at delivery, mean ± SD23.7 ± 5.6 Gestational age (wk) at delivery, mean ± SD38.4 ± 1.4 Baby\'s race/ethnicity, no. (%) Hispanic2 (3) African American70 (85) Mixed (\>1 race/ethnicity)10 (12) Parent with asthma, no. (%)52 (63) Parent with hay fever, no. (%)47 (64) Mother smoked during the first year of life, no. (%)33 (44)  1-y Outcomes No. of colds reported, mean ± SD4.2 ± 2.7 No. of wheezing illnesses reported, mean ± SD1.3 ± 1.7 ≥2 Wheezing episodes, no. (%)20 (27) Any hospitalization, no. (%)11 (15) Hospitalization for respiratory tract illness, no. (%)6 (8) Hospitalization for wheeze, no. (%)2 (3) Ear infection reported, no. (%)28 (37)

Respiratory tract virus in nasal lavage fluid {#sec2.2}
---------------------------------------------

We collected nasal lavage samples during symptomatic respiratory episodes (n = 38) and at routine 1-year follow-up visits (n = 64). Respiratory tract viruses were detected in 74% of the symptomatic episodes and in 48% of the routine visits ([Table II](#tbl2){ref-type="table"} ). Human rhinovirus was found with the highest frequency and RSV with the next highest frequency in subjects with symptomatic episodes, but both could also be detected in asymptomatic subjects. Together, the findings indicate that the majority of respiratory tract illnesses during the first year of life are associated with detectable levels of respiratory tract viral pathogens, but asymptomatic infants also have a high rate of apparent viral carriage.Table IIViruses detected in nasal samples during symptomatic episodes and the 12-month scheduled visitVirus detectedSymptomatic (n = 38)Scheduled visit (n = 64)Rhinoviruses31.6% (12)23.4% (15)Adenovirus5.3% (2)6.3% (4)RSV7.9% (3)3.1% (2)Coronaviruses2.6% (1)1.6% (1)Enterovirus2.6% (1)3.1% (2)Parainfluenza2.6% (1)1.6% (1)Influenza2.6% (1)0% (0)Metapneumovirus2.6% (1)0% (0)Bocavirus0% (0)1.6% (1)Multiple viruses[∗](#tblIIfnlowast){ref-type="table-fn"}15.8% (6)7.8% (5)  Virus detected73.7% (28)48.4% (31)[^1][^2]

Individual variation in response to RSV infection {#sec2.3}
-------------------------------------------------

The distribution of values for RSV-induced *IFNG* and *CCL5* mRNA, RSV RNA, and STAT1 activation showed a broad range among the subject population, suggesting a degree of individual variation among subjects for each of these responses ([Table III](#tbl3){ref-type="table"} ). This finding further suggests that the differences in responses might translate to variable degrees of protection against viral infection.Table IIIDistribution of antiviral responses among subjectsDistribution of antiviral responsesNo.MedianIQR*CCL5* mRNA response to RSV726.213.09-14.74*IFNG* mRNA response to RSV710.970.34-1.94RSV RNA copy number70213,918137,872-436,690STAT1 phosphorylation with IFN-β636.172.79-11.72[^3][^4]

Antiviral responses and respiratory tract infections during first year of life {#sec2.4}
------------------------------------------------------------------------------

We next investigated whether individual variation in antiviral response was associated with the development of respiratory tract infections during the first year of life. We found that *IFNG* responses to RSV in cord blood monocyte cultures correlated inversely with the number of upper respiratory tract infections during the first year of life (*r* = −0.42, *P* \< .001, [Fig 1](#fig1){ref-type="fig"} ). There was no correlation between *IFNG* response and available measures that might be associated with a subject\'s atopy (ie, number of parents with asthma, number of parents with hayfever, and presence of parental asthma at the time of initial screening). The relationship to respiratory tract infections was selective for the *IFNG* response because we found no association between CCL5 response, RSV titer, or STAT1 activation with the frequency of upper respiratory tract infections (*r* = −0.17, *P* = .17; *r* = −0.01, *P* = .94; and *r* = −0.02, *P* = .91, respectively). We found no association of *IFNG* response, CCL5 response, RSV titer, or STAT1 activation with the frequency of wheezing episodes in the first year of life (*r* = −0.05, *P* = .71; *r* = −0.12, *P* = .32; *r* = −0.04, *P* = .75; and *r* = 0.12, *P* = .36, respectively).Fig 1Association of antiviral responses at birth with the number of upper respiratory tract infections (colds) and wheezing episodes in the first year of life. **A,** The antiviral response of cord blood monocyte cultures was monitored by using RSV-induced increases in *CCL5* mRNA (n = 65), *IFNG* mRNA (n = 66), and RSV RNA (n = 63) and using IFN-β--dependent increases in STAT1 phosphorylation (n = 57). The relationship of these values to the reported occurrences for upper respiratory tract infections and wheezing episodes were analyzed by using the Spearman rank correlation coefficient. \*Significant inverse correlation. **B,** For conditions in Fig 1, *A*, the individual values for RSV induction of *IFNG* mRNA and the number of colds (n = 66). **C,** For conditions in Fig 1, *A*, analysis of the mean values for RSV induction of *IFNG* mRNA in relation to low, medium, or high number of reported colds (n = 66).

We also investigated whether there was an association of antiviral responses with the occurrence of infections at other respiratory and nonrespiratory sites (ie, sinus, ear, croup, and stomach), as well as any association with the number of reported hospitalizations for respiratory tract illness. We found that IFN-γ responses to RSV in cord blood monocyte cultures were inversely related to the frequency of ear infections (*P* = .01), sinus infections (*P* = .04), pneumonias (*P* = .02), and respiratory-related hospitalizations (*P* = .05, [Fig 2](#fig2){ref-type="fig"} ). We found no differences in IFN-γ responses between those who did and did not have croup, "stomach flu," or unexplained fevers ([Fig 2](#fig2){ref-type="fig"} and data not shown). Together, these findings reinforce the association of a decreased IFN-γ response to RSV with the development of increased viral respiratory tract infections in the first year of life.Fig 2Relationship of RSV induction of *IFNG* mRNA to the occurrences of ear infections (n = 25/66), croup (n = 6/66), sinus infections (n = 9/66), pneumonia (n = 4/66), and respiratory hospitalizations (n = 6/66) in the first year of life. There were no reported cases of stomach flu. The *IFNG* mRNA response to RSV infection was determined as described in the legend for Fig 1. The *boxes* represent the median *(middle line)* and interquartile range, and the *whiskers* extend out to show extreme values. Potential outliers are plotted as the *dashed lines* outside the whiskers. These are shown for groups without *(No)* and with *(Yes)* the indicated clinical condition.

Discussion {#sec3}
==========

In this study we provide evidence that a decreased antiviral interferon response at the time of birth is selectively associated with an increase in acute respiratory tract infections in the first year of life among infants at high risk for asthma and allergic disease. In support of this relationship between antiviral response and respiratory tract infection, we show that (1) RSV-driven induction of *IFNG* mRNA production in cord blood monocytes is variable among infants at birth; (2) decreased levels of RSV-induced *IFNG* mRNA in cord blood monocytes are associated with a significant increase in the frequency of upper respiratory tract infections, as well as the prevalence of ear infections, sinus infections, pneumonias, and respiratory tract illnesses requiring hospitalization; (3) levels of RSV-induced *CCL5* mRNA expression (another highly inducible antiviral system) and interferon-driven activation of STAT1 (the downstream target of the interferon receptors) are not associated with this phenotype for subsequent illness; (4) symptomatic respiratory tract illnesses were frequently associated with detectable levels of respiratory viral pathogens; and (5) levels of RSV-induced *IFNG* mRNA were not linked to other types of infections, such as croup or stomach flu, which are caused by other types of pathogens. Together, these findings provide for a close relationship between RSV-driven *IFNG* mRNA production and the development of viral respiratory tract illness and in turn suggest the possibility that a decrease in this type of response might lead to an increase in this type of illness.

The present findings offer distinct insights from those obtained previously. For example, others found that PHA- and allergen-stimulated IFN-γ production in CBMCs was inversely correlated with the frequency of viral respiratory tract infection in the first year of life.[@bib10], [@bib11] However, these studies likely measured the responsiveness of T cells because nonadherent cells were not eliminated and T-cell mitogen and antigen were used for stimulation. Moreover, the effect of viral infection itself was not assessed in these studies. Other studies examined the capacity of PBMCs to produce IFN-γ during RSV-induced illness in children, but in this case cells were activated with phorbol 12-myristate 13-acetate--ionomycin and cross-linking antibodies to T-cell costimulatory receptors, and the response was localized to CD3^+^ T cells.[@bib20] Similarly, others again made no attempt to purify cells and then stimulated cells with T-cell mitogen and did not separately quantify *IFNG* mRNA levels.[@bib21] The same approach was taken in previous reports of an association between decreased IFN-γ production from CBMCs and an increased risk of allergic sensitization and recurrent wheezing.[@bib12], [@bib22], [@bib23] Here again, this might reflect the focus on T-cell production of IFN-γ and the proposed role of T~H~1 versus T~H~2 cytokines in the development of atopy and asthma.

After these studies, we have come to better recognize the critical role of the innate immune system in controlling viral infection and postviral asthma.[@bib9] In particular, the interferon and monocyte-macrophage systems are required for protective immunity against respiratory tract viruses, such as RSV,[@bib24], [@bib25], [@bib26] and these same systems are capable of driving postviral asthma independent of the adaptive immune system, at least in experimental models.[@bib27], [@bib28], [@bib29] Therefore the present approach was designed to directly assess the innate immune response to viral infection and was done so by using the relevant cell type (purified monocytes) and stimulus (RSV infection), as well as more specific and sensitive methods (real-time quantitative PCR) than applied previously. The upshot is the first evidence that the monocyte *IFNG* gene also serves as a marker and might even participate in the susceptibility to infection during infancy. This unexpected finding provides a new lead for control of the antiviral response because the previous view was that *IFNG* gene expression was silenced in the monocyte lineage and was only active in lymphoid cells.[@bib30]

In that regard we note that IFN-γ production is generally attributed to natural killer (NK) cells, NKT cells, and T cells, whereas monocytes and macrophages are solely a target of IFN-γ action. Indeed, studies of atopic disease in infancy often focus exclusively on T-cell production of IFN-γ.[@bib31] This circumstance is also likely due to the lower levels of IFN-γ produced by monocytes and macrophages under conditions used in previous studies. Here we are able to measure IFN-γ production by using a sensitive assay for the corresponding mRNA. Whether this level of interferon production has functional consequences is uncertain, but its utility as a biomarker for susceptibility to viral infection proved quite useful. In contrast, it appears that the monocyte-macrophage lineage is critical for host defense against respiratory tract viruses (including RSV). In particular, lung macrophages are charged with clearance of infected cells without dying themselves, and this protection derives from an antiapoptotic survival function of the chemokine CCL5.[@bib25] If this function is lost (eg, in mice that are CCL5 deficient), the host is more susceptible to viral respiratory tract infection. Other work suggests that CCL5 is also needed to direct dendritic cell traffic in the face of viral infection.[@bib32] Each of these observations are consistent with those linking *CCL5* promoter gene polymorphisms to susceptibility to severe RSV-induced bronchiolitis.[@bib33] Nonetheless, we did not find that RSV induction of *CCL5* gene expression was significantly associated with viral respiratory tract infection rates in the first year of life. It is still possible, however, that CCL5 production at the level of the lung macrophage would be predictive of susceptibility to infection, especially given the heterogeneity of monocyte-macrophage populations in the circulation and the lung.

Our study was conducted in a population selected for high prevalence of atopic disease. However, we do not expect that *IFNG* response or viral susceptibility is attributable to atopy. Indeed, we found no association of the *IFNG* response with the available measures associated with atopy in our subject group because full evaluation of atopic status in our subjects was not yet performed at 1 year of age. Similarly, others found no association between lower respiratory tract illness in the first year of life and the occurrence of parental atopy or subject eczema.[@bib11] These findings suggest that viral susceptibility can be independent of atopy, and certainly there is evidence that this can be the case in experimental models of viral respiratory tract infection.[@bib25] However, it will require a nonatopic cohort, follow-up of the present cohort, or both to formally test the relationship between virus-induced IFN-γ production in monocytes, viral susceptibility, and atopic status in human subjects.

The molecular mechanism for RSV induction of *IFNG* gene expression still needs to be defined. Thus the pathogen recognition receptor system is responsible for mediating viral induction of the various forms of IFN-α, IFN-β, and IFN-λ, and RSV is remarkably effective in blocking the induction (and signaling) of these interferon species.[@bib34], [@bib35] By contrast, the pathogen recognition receptor system of Toll-like receptors and retinoic acid inducible gene I (RIG-I)-like receptors (RLRs) does not appear to regulate *IFNG* gene expression or signaling. Instead, *IFNG* gene expression is subject to a distinct type of positive and negative regulation at pretranscriptional, transcriptional, and posttranscriptional levels, at least in the case of lymphoid (NK, NKT, and T) cells.[@bib30] However, these regulatory mechanisms have not been studied in monocytes or in response to RSV in any cell type. We could not define this regulatory mechanism with such limited human samples, but our work should open this new field of research.

RSV is the most common cause of serious respiratory tract illness during infancy, and severe RSV-induced bronchiolitis is linked to subsequent wheezing illness/asthma. Furthermore, paramyxoviral infection is established as a high-fidelity experimental model of asthma. Moreover, RSV and related paramyxoviruses are easily detected in monocytes and macrophages in the lung. Hence we chose RSV for our study of newborns and their monocytes, unaware of course that the subsequent results would predict respiratory tract illness associated with rhinovirus. With such a severe limitation in cell sample size, we were unable to test multiple viruses, but an analysis of the response to other types of viruses (including rhinovirus) and viral strains (including other RSV types) would be a valuable goal in the future.

In summary, we report that congenital variations in the innate immune response might predict the susceptibility to acute respiratory tract illness during the first year of life. Our effort uncovered evidence that the *IFNG* mRNA monocyte response to virus rather than T-cell response to mitogen/allergen might be linked to the development of viral infections and eventually postviral asthma. We were able to define this relationship despite a relatively small sample size. Sample availability for complex immunologic analysis served to limit the number of URECA participants that could be studied. However, the demographic characteristics of our cohort were no different from those of the overall group, suggesting that we studied a representative sample of subjects. In addition, our study included mostly African American children, and therefore the result might not be generalized to children with other racial backgrounds. Interestingly, others have recently found that interferon-stimulated genes (eg, *PYHIN1*) are also linked to the development of asthma, particularly in subjects of African descent.[@bib36] Our findings are also consistent with observations of decreased IFN-γ production in response to RSV in PBMCs from older children and adults with allergic asthma.[@bib37], [@bib38] Thus these early events in infancy might carry over to a similar deficit in antiviral defense in later life. Together, the findings suggest that a full analysis of interferon production pathways might provide key insights into the susceptibility to viral respiratory tract infection and subsequent chronic obstructive lung diseases, such as asthma.Clinical implicationsIndividual variations in the immune response to respiratory tract viruses are detectable at birth, and these differences predict the susceptibility to acute respiratory tract illness during first year of life.

Appendix {#appsec1}
========

Table E1Characteristics of the group included in the present study compared with the group that was not includedSubjects\' characteristicsSubjects in the analysis group (n = 82)Subjects not in the analysis group (n = 96)*P* valueBaseline demographics Female sex, no. (%)46 (56)46 (48).28 Age of mother (y) at delivery, mean ± SD23.7 ± 5.623.9 ± 5.2.66 Gestational age (wk) at delivery, mean ± SD38.4 ± 1.438.4 ± 1.5.71 Baby\'s race/ethnicity, no. (%).22 Hispanic2 (3)2 (2) African American70 (85)87 (91) Mixed (\>1 race/ethnicity)10 (12)5 (5) Parent with asthma52 (63)48 (50).43 Parent with hay fever47 (64)42 (49).06 Mother smoked during first year of life33 (44)43 (38).581-y Outcomes No. of colds reported, mean ± SD4.2 ± 2.73.9 ± 2.9.48 No. of wheezing illnesses reported, mean ± SD1.3 ± 1.71.5 ± 2.2.58 ≥2 Wheezing episodes, no. (%)20 (27)28 (32).50 Any hospitalization11 (15)18 (20).35 Hospitalization for respiratory tract illness6 (8)7 (8).97 Hospitalization for wheeze2 (3)1 (1).46 Ear infection reported28 (37)40 (45).32
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[^1]: Values in parentheses indicate numbers of patients.

[^2]: More than 1 respiratory tract virus detected.

[^3]: Definition of antiviral responses: *CCL5* mRNA response to RSV = *CCL5* mRNA copies with RSV/*CCL5* mRNA copies without RSV, *IFNG* mRNA response to RSV = *IFNG* mRNA copies with RSV/*IFNG* mRNA copies without RSV, RSV RNA copy number = RSV RNA copy number with RSV infection--Without infection, STAT1 phosphorylation with IFN-β = (P-STAT1 with IFN-β/Total STAT1 with IFN-β)/(P-STAT1 without IFN-β/Total STAT1 without IFN-β).

[^4]: *IQR*, Interquartile range.
